KLRB1 and prostate carcinoma: Similarly, in prostate cancer [18], non-small-cell lung cancer [15], and triple-negative breast cancer [45], the enhanced interaction between CD161 and its upstream molecule LLT1 inhibits the cytotoxic activity mediated by NK cells.